Skip to main content
. 2020 Jul 24;10:1240. doi: 10.3389/fonc.2020.01240

Figure 3.

Figure 3

Saliva-based EFIRM for detection of p.L858R EGFR and p.E545K PIK3CA in Case 2. (A) The volume of metastatic tumor showed an obvious decrease after LAT and initiation with 80 mg osimertinib. (B) The change trends of p.L858R EGFR EFIRM data have significant similarities with plasma-based ddPCR for p.L858R EGFR (R = 0.467, P = 0.04). (C) The p.E545K PIK3CA tested by plasma-based NGS remained undetectable till to day 315, which showed the only and unapparent peak (from 0 to 0.2%). On the contrary, the EFIRM signal of p.E545K PIK3CA mutation increased gradually from the beginning.